Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus

Gastroenterology

Volumn 140, Issue 2, 2011, Pages 667-675

  Shimakami, Tetsuro ^a   Welsch, Christoph ^a,b,c   Yamane, Daisuke ^a   McGivern, David R ^a   Yi, Minkyung ^d   Zeuzem, Stefan ^b   Lemon, Stanley M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b GOETHE UNIVERSITY   (Germany)

^c MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Antiviral Drug; NS3 4A Protease; Viral Assembly; Viral Replication

Indexed keywords

MONTIRELIN; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; GENOTYPE; HEPATITIS C VIRUS; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REPLICON; RNA REPLICATION; VIRUS ASSEMBLY; VIRUS INFECTIVITY; VIRUS MUTANT; VIRUS MUTATION; VIRUS PARTICLE; VIRUS RELEASE; VIRUS REPLICATION; WILD TYPE;

EID: 79251561245     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.10.056     Document Type: Article

References (28)

1. M. Fried, M. Shiffman, and K. Reddy Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
2. J. McHutchison, G. Everson, and S. Gordon Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838
3. C. Hzode, N. Forestier, and G. Dusheiko Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 2009 1839 1850
4. C. Sarrazin, R. Rouzier, and F. Wagner SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders Gastroenterology 132 2007 1270 1278
5. H. Reesink, G. Fanning, and K. Farha Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients Gastroenterology 138 2010 913 921
6. S. Seiwert, S. Andrews, and Y. Jiang Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227) Antimicrob Agents Chemother 52 2008 4432 4441
7. N. Liverton, S. Carroll, and J. Dimuzio MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease Antimicrob Agents Chemother 54 2010 305 311
8. C. Sarrazin, T. Kieffer, and D. Bartels Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir Gastroenterology 132 2007 1767 1777
9. S. Susser, C. Welsch, and Y. Wang Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients Hepatology 50 2009 1709 1718
10. D. Bartels, Y. Zhou, and E. Zhang Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects J Infect Dis 198 2008 800 807
11. T. Kuntzen, J. Timm, and A. Berical Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-nave patients Hepatology 48 2008 1769 1778
12. T. Shimakami, R.E. Lanford, and S.M. Lemon Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities Curr Opin Pharmacol 9 2009 537 544
13. E. Domingo, L. Menndez-Arias, and J. Holland RNA virus fitness Rev Med Virol 7 1997 87 96
14. C. Lin, C. Gates, and B. Rao In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061 J Biol Chem 280 2005 36784 36791
15. M. Yi, X. Tong, and A. Skelton Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor Reduced RNA replication fitness and partial rescue by second-site mutations J Biol Chem 281 2006 8205 8215
16. X. Tong, S. Bogen, and R. Chase Characterization of resistance mutations against HCV ketoamide protease inhibitors Antiviral Res 77 2008 177 185
17. Y. He, M. King, and D. Kempf Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system Antimicrob Agents Chemother 52 2008 1101 1110
18. Y. Zhou, D. Bartels, and B. Hanzelka Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease Antimicrob Agents Chemother 52 2008 110 120
19. X. Tong, R. Chase, and A. Skelton Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034 Antiviral Res 70 2006 28 38
20. Y. Zhou, U. Mh, and B. Hanzelka Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha J Biol Chem 282 2007 22619 22628
21. Y. Ma, J. Yates, and Y. Liang NS3 helicase domains involved in infectious intracellular hepatitis C virus particle assembly J Virol 82 2008 7624 7639
22. M. Yi, R. Villanueva, and D. Thomas Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells Proc Natl Acad Sci U S A 103 2006 2310 2315
23. A.U. Neumann, N.P. Lam, and H. Dahari Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy Science 282 1998 103 107
24. M. Yi, and S.M. Lemon Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells J Virol 78 2004 7904 7915
25. S.M. Lemon Induction and evasion of innate antiviral responses by hepatitis C virus J Biol Chem 285 2010 22741 22747
26. Y. Ma, M. Anantpadma, and J.M. Timpe Hepatitis C virus NS2 protein serves as a scaffold for virus assembly by interacting with both structural and nonstructural proteins J Virol 85 2011 86 97
27. N. Yao, P. Reichert, and S.S. Taremi Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase Structure Fold Des 7 1999 1353 1363
28. A.Y. Howe, R. Chase, and S.S. Taremi A novel recombinant single-chain hepatitis C virus NS3-NS4A protein with improved helicase activity Protein Science 8 1999 1332 1341